What is MAIA Biotechnology Inc.'s earnings per share (EPS)?

MAIA Biotechnology Inc. (MAIA) reported diluted earnings per share of $-0.70 for fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MAIA Biotechnology Inc. Financials

MAIA

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows MAIA Biotechnology Inc. (MAIA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, MAIA Biotechnology Inc. generates $0.84 in operating cash flow (-$18.8M OCF vs -$22.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$22.4M

YoY+3.7%

MAIA Biotechnology Inc. reported -$22.4M in net income in fiscal year 2025. This represents an increase of 3.7% from the prior year.

EPS (Diluted)

$-0.70

YoY+33.3%

MAIA Biotechnology Inc. earned $-0.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

61M

YoY+131.9%

MAIA Biotechnology Inc. had 61M shares outstanding in fiscal year 2025. This represents an increase of 131.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$454K

YoY-95.5%

MAIA Biotechnology Inc. invested $454K in research and development in fiscal year 2025. This represents a decrease of 95.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

MAIA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	$0	$0	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$454K-95.5%	$10.0M-9.9%	$11.1M+24.4%	$8.9M+155.5%	$3.5M
SG&A Expenses	$9.7M+39.9%	$6.9M-23.4%	$9.1M+47.6%	$6.1M+43.2%	$4.3M
Operating Income	-$24.3M-43.1%	-$17.0M+16.0%	-$20.2M-24.8%	-$16.2M-107.7%	-$7.8M
Interest Expense	N/A	$57-99.2%	$7K-1.5%	$7K-99.2%	$828K
Income Tax	$2K	N/A	N/A	N/A	N/A
Net Income	-$22.4M+3.7%	-$23.3M-17.6%	-$19.8M-25.4%	-$15.8M-25.4%	-$12.6M
EPS (Diluted)	$-0.70+33.3%	$-1.05+29.5%	$-1.49+14.9%	$-1.75+26.2%	$-2.37

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$6.4M+104.4%	$3.1M-2.7%	$3.2M	N/A	$2.7M+30.0%	$2.1M-11.6%	$2.3M	N/A
SG&A Expenses	$3.0M+46.1%	$2.1M-7.8%	$2.2M	N/A	$1.5M-13.7%	$1.8M+8.3%	$1.6M	N/A
Operating Income	-$9.4M-81.2%	-$5.2M+4.8%	-$5.4M	N/A	-$4.2M-9.8%	-$3.8M+3.4%	-$3.9M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$85	N/A	N/A	N/A
Income Tax	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Net Income	-$8.9M-66.5%	-$5.3M-18.4%	-$4.5M	N/A	-$2.7M+69.2%	-$8.9M-10.1%	-$8.1M	N/A
EPS (Diluted)	$-0.27-50.0%	$-0.18-12.5%	$-0.16	N/A	$-0.11+72.5%	$-0.40+13.0%	$-0.46	N/A

MAIA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	N/A	$10.2M+34.2%	$7.6M-37.1%	$12.0M+6.1%	$11.3M
Current Assets	N/A	$10.2M+34.2%	$7.6M-35.9%	$11.8M+10.6%	$10.7M
Cash & Equivalents	N/A	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$6.5M-8.0%	$7.1M+101.7%	$3.5M+63.8%	$2.1M
Current Liabilities	N/A	$3.8M-22.4%	$4.9M+51.0%	$3.3M+52.3%	$2.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$3.6M+661.2%	$478K-94.4%	$8.5M-7.3%	$9.2M
Retained Earnings	N/A	-$87.2M-36.3%	-$64.0M-44.7%	-$44.2M-55.5%	-$28.4M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$11.8M+6.7%	$11.0M-6.9%	$11.9M+16.8%	$10.2M+9.9%	$9.2M-23.1%	$12.0M+37.9%	$8.7M+15.2%	$7.6M
Current Assets	$11.8M+6.4%	$11.0M-6.9%	$11.9M+16.8%	$10.2M+9.9%	$9.2M-23.1%	$12.0M+38.1%	$8.7M+15.0%	$7.6M
Cash & Equivalents	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.7M+63.8%	$7.2M+3.6%	$6.9M+6.2%	$6.5M-14.5%	$7.6M-13.9%	$8.9M-38.8%	$14.5M+104.3%	$7.1M
Current Liabilities	$10.0M+98.1%	$5.0M-0.3%	$5.1M+32.0%	$3.8M+6.1%	$3.6M+2.8%	$3.5M-28.5%	$4.9M-0.6%	$4.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$42K-98.9%	$3.9M-21.6%	$4.9M+36.0%	$3.6M+124.6%	$1.6M-48.8%	$3.2M+154.8%	-$5.8M-1307.3%	$478K
Retained Earnings	-$106.0M-9.2%	-$97.1M-5.8%	-$91.8M-5.2%	-$87.2M-4.3%	-$83.7M-3.4%	-$80.9M-12.3%	-$72.0M-12.6%	-$64.0M

MAIA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$18.8M-20.0%	-$15.7M-20.1%	-$13.1M-8.1%	-$12.1M-193.4%	-$4.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$17.9M-1.5%	$18.2M+96.1%	$9.3M-25.7%	$12.5M-11.1%	$14.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.5M+15.7%	-$4.1M+1.6%	-$4.2M-7.5%	-$3.9M-10.9%	-$3.5M+24.8%	-$4.7M-30.6%	-$3.6M+10.2%	-$4.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4.2M+24.3%	$3.4M-37.6%	$5.5M+12.7%	$4.8M+673.0%	$627K-92.2%	$8.0M+69.3%	$4.7M-6.1%	$5.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MAIA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-639.8%+3501.0pp	-4140.8%-3955.5pp	-185.3%-48.3pp	-137.0%
Return on Assets	N/A	-229.0%+32.3pp	-261.3%-130.1pp	-131.2%-20.1pp	-111.0%
Current Ratio	N/A	2.65+1.1	1.53-2.1	3.61-1.4	4.97
Debt-to-Equity	N/A	1.79-13.1	14.85+14.4	0.41+0.2	0.23
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-21365.9%-21228.0pp	-137.9%-46.5pp	-91.4%	N/A	-169.0%+111.8pp	-280.8%	N/A	N/A
Return on Assets	-75.6%-27.2pp	-48.4%-10.3pp	-38.1%	N/A	-29.6%+44.3pp	-73.9%+18.7pp	-92.6%	N/A
Current Ratio	1.18-1.0	2.19-0.2	2.35-0.3	2.65+0.1	2.56-0.9	3.42+1.6	1.77+0.2	1.53
Debt-to-Equity	281.75+279.9	1.85+0.4	1.40-0.4	1.79-2.9	4.71+1.9	2.80+5.3	-2.51-17.4	14.85
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cue Biopharma Inc CUE

$22.1M

Pds Biotechnology Corporation PDSB

$29.4M

Bioxcel Therapeutics Inc BTAI

$29.5M

ARTIVA BIOTHERAPEUTICS INC ARTV

$134.7M

Quantum BioPharma Ltd QNTM

$18.0M

Frequently Asked Questions

Is MAIA Biotechnology Inc. profitable?

No, MAIA Biotechnology Inc. (MAIA) reported a net income of -$22.4M in fiscal year 2025.

What is MAIA Biotechnology Inc.'s operating cash flow?

MAIA Biotechnology Inc. (MAIA) generated -$18.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does MAIA Biotechnology Inc. spend on research and development?

MAIA Biotechnology Inc. (MAIA) invested $454K in research and development during fiscal year 2025.

How many shares does MAIA Biotechnology Inc. have outstanding?

MAIA Biotechnology Inc. (MAIA) had 61M shares outstanding as of fiscal year 2025.

Are MAIA Biotechnology Inc.'s earnings high quality?

MAIA Biotechnology Inc. (MAIA) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.